VERTICINONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H43NO3
Molecular Weight	429.6352
Optical Activity	UNSPECIFIED
Defined Stereocenters	12 / 12
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@]3([H])[C@@]([H])(CC(=O)[C@@]4([H])C[C@@H](O)CC[C@]34C)[C@]1([H])CC[C@@]5([H])[C@@]2([H])CN6C[C@@H](C)CC[C@@]6([H])[C@@]5(C)O

InChI

InChIKey=IQDIERHFZVCNRZ-YUYPDVIUSA-N

InChI=1S/C27H43NO3/c1-15-4-7-25-27(3,31)21-6-5-17-18(20(21)14-28(25)13-15)11-22-19(17)12-24(30)23-10-16(29)8-9-26(22,23)2/h15-23,25,29,31H,4-14H2,1-3H3/t15-,16-,17+,18+,19-,20-,21-,22-,23+,25-,26+,27-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28496003 | https://www.ncbi.nlm.nih.gov/pubmed/21881221 | https://www.ncbi.nlm.nih.gov/pubmed/25514053 | https://www.ncbi.nlm.nih.gov/pubmed/21958967

Verticinone is a major alkaloid isolated from the bulbus of Fritillaria ussuriensis. Verticinone was rapidly absorbed, widely distributed in most tissues, and metabolized extensively before excretion. Verticinone has antitumor effects - treatment with verticinone can induce cancer cell apoptosis and autophagy via modulating the production of metabolites, which are supportive of carcinoma cell proliferation. Due to the potent antitussive activity and no addictive effect, verticinone seems to be a promising potential antitussive drug. Verticinone is expected to become a potentially novel sedative-analgesic agent without producing tolerance and dependence.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Angiotensin-converting enzyme 97 Target ID: CHEMBL2625 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12865981	Inhibitor 8297	165.0 µM [IC50]
Apoptosis 155 Target ID: map04210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28496003	Activator 1430
autophagy 17 Target ID: GO:0006914 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28496003	Activator 1430

Conditions

Condition	Modality	Highest Phase	Product
Cough 106 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21958967	Preventing	Preclinical	Unknown Approved Use Unknown
Promyelocytic leukemia 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12419949	Primary	Basic research	Unknown Approved Use Unknown
Colorectal cancer 101 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28496003	Primary	Basic research	Unknown Approved Use Unknown
Oral cancer 13 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18058993	Primary	Basic research	Unknown Approved Use Unknown
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21881221	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Mice: 3 mg/kg

Route of Administration: Oral

In Vitro Use Guide

When HL-60 cells were incubated with 7.5 uM of verticinone for 4 d, 44% of the cells became nitroblue tetrazolium (NBT) positive.

Name

Type

Language

VERTICINONE

Common Name

English

CEVAN-6-ONE, 3,20-DIHYDROXY-, (3.BETA.,5.ALPHA.)-

Systematic Name

English

FRITILLARINE

Common Name

English

OSNOVANINE

Common Name

English

PEIMININE

Common Name

English

RADDEANINE

Common Name

English

IMPERIALINE [MI]

Common Name

English

Code System Code Type Description

FDA UNII

QUB07U6VTQ